Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of GTx-024 (enobosarm) in ER+/AR+ Metastatic or Locally Advanced Breast Cancer
2015-001012-35Phase 2Terminated
- Sponsor
- GTx
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enobosarm in breast cancer (2 arms), sponsored by GTx. Primary endpoint: Clinical benefit rate at 24 weeks. Started Jul 2015; status: terminated.
02
Drugs
enobosarm
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-001012-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001012-35.